Blood Disorders Treatment Market Trends in 2026

Three adeno-associated virus (AAV) gene therapies for hemophilia received approval in the Western markets between 2022 and 2024: CSL Behring’s Hemgenix (etranacogene dezaparvovec) for hemophilia B, BioMarin’s Roctavian (valoctocogene roxaparvovec) for hemophilia A, and Pfizer’s Beqvez (fidanacogene elaparvovec) for hemophilia B. They offered the prospect of a one-time treatment that could reduce the need for regular factor infusions. Commercial uptake told a very different story. Pfizer discontinued Beqvez in February 2025 without a single commercial patient dosed; BioMarin has scaled back and subsequently withdrawn Roctavian from parts of its original launch footprint; and Hemgenix has faced supply constraints through much of 2026.

Pfizer cited limited interest among patients and physicians when it explained the decision to discontinue Beqvez.

Physician research points to a reset in expectations rather than a rejection of gene therapy. The proportion of EU4 & UK hematologists seeking longer-term efficacy data before referring to a hemophilia A patient for gene therapy rose from 66.0% in 2025 to 89.0% in 2026. Meanwhile, established prophylaxis continues to perform commercially: Sanofi reported €674 million in first-half 2026 sales for its extended half-life factor VIII product Altuviiio. That sales figure shows the scale of the alternative, although it does not establish how much demand shifted specifically from gene therapy or non-factor medicines.

The late-2023 approvals of CRISPR-based Casgevy (exagamglogene autotemcel) and lentiviral Lyfgenia (lovotibeglogene autotemcel) made sickle cell disease (SCD) a leading test case for genetic medicine. Yet hematologists do not expect a single modality to serve every patient.

The unmet need helps explain interest in a wider range of treatments. Seven in ten surveyed hematologists rated unmet need in SCD as high, and they estimated that 51.0% of their patients were not optimally managed with current therapy. After positive Phase III HIBISCUS results, 57.0% reported significant interest in prescribing etavopivat, compared with 42.0% in 2025. Gene-editing programs also continue to advance. Beam announced a USD 500 million strategic financing facility with Sixth Street in February 2026 to support the potential launch of its separate sickle cell candidate, risto-cel.

Treatment for paroxysmal nocturnal hemoglobinuria (PNH) now includes C5 inhibitors and three proximal complement approaches: Apellis’ pegcetacoplan targets C3, Novartis’ iptacopan targets factor B, and AstraZeneca’s danicopan targets factor D as an add-on to C5 inhibition. These drugs address different aspects of hemolysis and give clinicians more options when residual anemia persists. A separate mechanism has now reached warm autoimmune hemolytic anemia (wAIHA). In August 2026, the FDA approved Johnson & Johnson’s Imaavy (nipocalimab-aahu), an FcRn blocker that reduces pathogenic IgG antibodies, for patients aged 12 years and older who are currently or were previously treated with corticosteroids. It was the first FDA-approved treatment specifically for wAIHA.

About one in 8,000 people live with wAIHA. Before Imaavy’s approval, treatment relied on corticosteroids and other immunosuppressive therapies without a disease-specific FDA-approved option. In the Phase II/III ENERGY study, approximately three times as many patients receiving the approved Imaavy dose achieved a durable hemoglobin response by week 24 as those receiving placebo. Fatigue scores also improved. PNH developers continue to refine the use of complement inhibitors, while the wAIHA approval establishes a separate, antibody-directed route for another hemolytic condition.

Incyte’s 2026 acquisition of Vega Therapeutics, a wholly owned Star Therapeutics subsidiary, shows the strategic appeal of rare, non-malignant hematology. Incyte paid USD 1.25 billion upfront, with Star eligible for up to USD 750 million in additional sales milestone payments. The transaction brought VGA039, an investigational Phase III antibody directed at Protein S. Its once-monthly, self-administered subcutaneous regimen is being studied as prophylaxis for von Willebrand disease (VWD). Approximately 135,000 people in the United States have been diagnosed with VWD; that figure should not be read as the eligible population for VGA039.

The acquisition follows earlier investment in rare hematology, including Pfizer’s 2022 purchase of Global Blood Therapeutics for its sickle cell portfolio. Beam’s separate USD 500 million financing agreement with Sixth Street is another sign of capital flowing to the field, although it is financing rather than an acquisition.

Blood counts and smear review are central to hematology, but some workflows still require significant manual effort. Image-based systems are expanding the options. In February 2026, Athelas, a Commure company, announced FDA clearance for point-of-care use of its CLIA-waived Athelas Home analyzer. The device provides white blood cell and neutrophil percentage results from a fingerstick sample in minutes, using neural-network-based cell analysis and computer vision. Its cleared outputs should not be described as a full complete blood count.

Digital morphology is developing in parallel. Scopio Labs received FDA clearance for its Full Field Peripheral Blood Smear application in 2020, with subsequent clearances for related platforms and capabilities. Scopio has estimated that roughly 120,000 laboratories worldwide perform about 600 million peripheral blood smear tests annually, many using manual microscopy. Sight Diagnostics’ OLO analyzer has FDA 510(k) clearance for use in CLIA non-waived settings and uses computer vision to deliver a five-part differential complete blood count. Its U.S. clearance should not be confused with a CLIA waiver for routine use in small practices or pharmacies.

The next test for blood disorders treatment is whether new options can become part of routine care. Regulatory approval establishes that a product can be used in a defined population. It does not resolve every question a hematologist, patient, treatment center or payer faces when deciding whether to use it. Across the five trends, adoption increasingly depends on the strength of long-term evidence, the work required to deliver treatment and the ability to identify patients who are likely to benefit.

Hemophilia gene therapy makes that distinction particularly clear. A one-time infusion can be appealing to someone who has spent years managing regular prophylaxis, but the decision carries a different kind of uncertainty. Patients and physicians must weigh the prospect of sustained bleed protection against questions about how long the benefit will last and what future treatment choices may remain available. Extended half-life factor products and non-factor prophylaxis have improved the alternatives available today. Gene therapy developers therefore need to demonstrate a durable advantage that matters to patients, rather than relying on the appeal of a one-time intervention alone.

In sickle cell disease, the challenge is also practical. Genetic therapies may offer substantial benefit to eligible patients, but treatment requires specialist capacity, coordination and a willingness to undergo an intensive process. Oral disease-modifying agents could serve a broader group if clinical results support their use, including patients who cannot access or do not wish to pursue genetic treatment. The two approaches need not follow the same adoption path. Physicians will position them according to disease severity, expected benefit, treatment burden and patient preference.

The emerging choices in hemolytic disorders bring a different question: which mechanism is appropriate for which patient? In PNH, several complement targets give clinicians options for addressing persistent hemolysis and anemia. In wAIHA, FcRn blockade addresses disease-driving autoantibodies through a distinct pathway. As these choices expand, evidence about response, safety and switching between therapies will become more useful to clinicians than a simple comparison of mechanisms. Companies that generate clear evidence for treatment decisions will be better placed to explain where their products fit.

Diagnostics can help make those decisions timelier, provided their role is defined precisely. A point-of-care white blood cell result, and a digitized peripheral blood smear answer different clinical questions; neither replaces every test performed by a central laboratory. Their value lies in making specific steps in diagnosis or monitoring more accessible and consistent within their cleared uses. That distinction matters as treatment grows more individualized and follow-up becomes more important.

For developers and acquirers, the commercial implication runs through all five trends. A differentiated mechanism or convenient dosing schedule can attract investment, as the Vega transaction illustrates. Lasting uptake, however, will depend on evidence that helps clinicians select patients, treatment pathways that providers can deliver, and access arrangements patients can navigate. The strongest hematology portfolios will connect those elements early in development, so that clinical promise can translate into care.

Blood disorders treatment in 2026 is changing along several related paths. Hemophilia gene therapy faces a more demanding commercial and evidence environment. In sickle cell disease, interest in oral, mechanism-specific drugs is growing alongside genetic approaches. Complement inhibitors are broadening PNH treatment choices, while FcRn blockade has introduced a disease-specific option for wAIHA. Incyte’s Vega acquisition highlights the value placed on a differentiated bleeding-disorder asset, and cleared imaging tools are creating new options for hematology testing and review.